C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy

被引:14
|
作者
Friedman, AN
Hunsicker, LG
Selhub, J
Bostom, AG
机构
[1] Indiana Univ, Sch Med, Div Nephrol, Indianapolis, IN 46202 USA
[2] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA USA
[3] Tufts Univ, Human Nutr Res Ctr Aging, Dept Agr, Boston, MA USA
[4] Rhode Isl Hosp, Div Renal Dis, Providence, RI USA
关键词
C-reactive protein; cardiovascular; arteriosclerosis; diabetes; nephropathy; Irbesartan Diabetic Nephropathy Trial;
D O I
10.1111/j.1523-1755.2005.00456.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
C-reactive protein as a predictor of total arteriosclerotic outcomes in type 2 diabetic nephropathy. Background. The inflammatory marker C-reactive protein (CRP) has been found in most, but not all, prospective studies to be associated with future cardiovascular outcomes. However, CRP has not been tested in the high-cardiovascular risk population of type 2 diabetic nephropathy. Methods. We studied the independent relationship between CRP and the subsequent development of incident or recurrent arteriosclerotic outcomes (primary) and congestive heart failure events (secondary) in 1560 individuals with diabetic nephropathy, overt proteinuria, and hypertension enrolled in the prospective Irbesartan Diabetic Nephropathy Trial. Results. Traditional cardiac risk factors were highly prevalent, CRP levels were high overall [quintiles (mg/L) 1st, 0 to 1.2; 2nd, 1.3 to 2.5; 3rd, 2.6 to 5.0; 4th, 5.1 to 10.0; and 5th, > 10), and subsequent cardiovascular events were very common. A univariate relationship existed between CRP and total arteriosclerotic outcomes (P < 0.0001). However, after adjusting for study intervention and traditional risk factors, the relationship no longer remained. In fact, controlling for previous cardiovascular disease alone caused the association to become nonsignificant. The secondary analysis found a significant univariate relationship between CRP and congestive heart failure events (P = 0.007) that persisted in multivariate analyses (P = 0.006). However, this relationship was confined to the highest CRP quintile [RR (95% CI) 2.0 (1.27, 3.16)]. Conclusion. In diabetic patients with nephropathy, CRP does not add predictive information above and beyond that provided by traditional established risk factors. Whether this holds true for other populations with similar risk burdens is an important public health question that should be addressed. A secondary finding of a link between CRP and congestive heart failure requires further confirmation.
引用
收藏
页码:773 / 778
页数:6
相关论文
共 50 条
  • [1] Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy
    Friedman, AN
    Hunsicker, LG
    Selhub, J
    Bostom, AG
    [J]. ATHEROSCLEROSIS, 2004, 172 (01) : 121 - 125
  • [2] Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients
    Chen-Chung Fu
    Du-An Wu
    Ji-hung Wang
    Wen-Chin Yang
    Chin-Hsiao Tseng
    [J]. Acta Diabetologica, 2009, 46
  • [3] Association of C-reactive protein and hyperuricemia with diabetic nephropathy in Chinese type 2 diabetic patients
    Fu, Chen-Chung
    Wu, Du-An
    Wang, Ji-hung
    Yang, Wen-Chin
    Tseng, Chin-Hsiao
    [J]. ACTA DIABETOLOGICA, 2009, 46 (02) : 127 - 134
  • [4] Association of C-Reactive Protein with Risk of Complications of diabetic nephropathy
    Zbaar, Sami A.
    Sarhat, Entedhar R. Rifaat
    Khalaf, Salim Jasim
    [J]. EGYPTIAN JOURNAL OF CHEMISTRY, 2022, 65 (08): : 483 - 487
  • [5] Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy
    Friedman, AN
    Hunsicker, LG
    Selhub, J
    Bostom, AG
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (11): : 3397 - 3402
  • [6] Implication of C-reactive protein in the pathogenesis of diabetic nephropathy.
    Babazono, T
    Tanaka, N
    Takeda, M
    Murata, H
    Iwamoto, Y
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 646A - 646A
  • [7] A prospective study of C-Reactive Protein and pooled cardiovascular disease outcomes in the irbesartan type 2 diabetic nephropathy trial cohort.
    Bostom, A
    Friedman, A
    Hunsicker, L
    Jacques, P
    Selhub, J
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 672A - 672A
  • [8] Uncoupling protein 2 G(-866)A polymorphism: a new gene polymorphism associated with C-reactive protein in type 2 diabetic patients C-reactive protein in type 2 diabetic patients
    Emanuela Lapice
    Michele Pinelli
    Elisabetta Pisu
    Antonella Monticelli
    Roberto Gambino
    Gianfranco Pagano
    Silvia Valsecchi
    Sergio Cocozza
    Gabriele Riccardi
    Olga Vaccaro
    [J]. Cardiovascular Diabetology, 9
  • [9] Microvascular oscillations and C-reactive protein in type 2 diabetic patients
    Schmiedel, O
    Harvey, JN
    [J]. DIABETES, 2004, 53 : A29 - A29
  • [10] C-reactive protein as predictor of death in end-stage diabetic nephropathy:: Role of peripheral arterial disease
    Böger, CA
    Götz, A
    Stubanus, M
    Banas, B
    Deinzer, M
    Krüger, B
    Holmer, SR
    Schmitz, G
    Riegger, GAJ
    Krämer, BK
    [J]. KIDNEY INTERNATIONAL, 2005, 68 (01) : 217 - 227